2023-505605-16-00RecruitingPhase 1/2
Kidney cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 105 (estimated)
- First submitted
- 2 Jun 2023
- Start date
- 24 Apr 2024
- Lead sponsor
- Oncorena AB
- Diseases
- Kidney cancer
- EU CT number
- 2023-505605-16-00
- EudraCT number
- 2020-005651-21
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 105
- 5 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic kidney cancer (clear cell or papillary type) who also have end-stage kidney disease.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Metastatic clear cell renal cell carcinoma or papillary renal cell carcinoma, together with end-stage renal disease
Read by machine on 9 Nov 2026.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Micancer Center S.L.P. | Lleida | Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Recruiting |
| Institut Gustave Roussy | Villejuif | France | Recruiting |
| Start Research Portugal Unipessoal Lda. | Lisbon | Portugal | Recruiting |
| Karolinska University Hospital | Solna | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.